Skip to main content
Erschienen in: The Patient - Patient-Centered Outcomes Research 4/2019

01.08.2019 | Original Research Article

EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery

verfasst von: Mihir Gandhi, Marcus Ang, Kelvin Teo, Chee Wai Wong, Yvonne Chung-Hsi Wei, Rachel Lee-Yin Tan, Mathieu F. Janssen, Nan Luo

Erschienen in: The Patient - Patient-Centered Outcomes Research | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

It is not clear whether 5-level EQ-5D (EQ-5D-5L) utilities based on recently developed value sets are more responsive than 3-level EQ-5D (EQ-5D-3L) utilities.

Objectives

The study aims were to compare (1) the responsiveness of EQ-5D-5L and EQ-5D-3L utilities and (2) the responsiveness of these utilities with the Short Form–6 Dimension (SF-6D) and Health Utilities Index Mark 3 (HUI3) utilities to the treatment benefit of cataract surgery.

Methods

A total of 148 patients were interviewed before and after their cataract surgery using EQ-5D-3L, EQ-5D-5L, SF-6D, and HUI3. Responsiveness was assessed for all measures using the mean change (post-treatment—pre-treatment), standardized effect size (SES), standardized response mean (SRM), and F-statistic.

Results

Using the Singapore value sets, mean change for EQ-5D-3L and EQ-5D-5L utilities was 0.016 and 0.028, SES was 0.097 and 0.199; SRM was 0.091 and 0.196; and F-statistic was 1.2 and 5.7, respectively. Similar trends were observed using the UK/England EQ-5D value sets, although the magnitude was slightly smaller. The mean change, SES, SRM and F-statistics for SF-6D (UK value set) were 0.020, 0.234, 0.249, and 9.2, respectively. The values of mean change, SES, SRM and F-statistics for HUI3 (Canada value set) were 0.080, 0.472, 0.474, and 33.3, respectively.

Conclusions

The EQ-5D-5L utilities tend to be more responsive than the EQ-5D-3L utilities to treatment benefits of cataract surgery. The HUI3 utilities are more responsive than both the EQ-5D-5L and SF-6D, and SF-6D utilities may be slightly more responsive than the EQ-5D-5L for assessing patients undergoing cataract surgery.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Longworth L, Yang Y, Young T, Mulhern B, Alava MH, Mukuria C, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess. 2014;18(9):1–224.CrossRef Longworth L, Yang Y, Young T, Mulhern B, Alava MH, Mukuria C, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess. 2014;18(9):1–224.CrossRef
2.
Zurück zum Zitat Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.CrossRef Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.CrossRef
3.
Zurück zum Zitat Agborsangaya CB, Lahtinen M, Cooke T, Johnson JA. Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population. Health Quality Life Outcomes. 2014;12(1):74.CrossRef Agborsangaya CB, Lahtinen M, Cooke T, Johnson JA. Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population. Health Quality Life Outcomes. 2014;12(1):74.CrossRef
4.
Zurück zum Zitat Feng Y, Devlin N, Herdman M. Assessing the health of the general population in England: how do the three-and five-level versions of EQ-5D compare? Health Quality Life Outcomes. 2015;13(1):171.CrossRef Feng Y, Devlin N, Herdman M. Assessing the health of the general population in England: how do the three-and five-level versions of EQ-5D compare? Health Quality Life Outcomes. 2015;13(1):171.CrossRef
5.
Zurück zum Zitat Janssen M, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–27.CrossRef Janssen M, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–27.CrossRef
6.
Zurück zum Zitat Pan C-W, Sun H-P, Wang X, Ma Q, Xu Y, Luo N, et al. The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients. Qual Life Res. 2015;24(7):1767–74.CrossRef Pan C-W, Sun H-P, Wang X, Ma Q, Xu Y, Luo N, et al. The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients. Qual Life Res. 2015;24(7):1767–74.CrossRef
7.
Zurück zum Zitat Wang P, Luo N, Tai E, Thumboo J. The EQ-5D-5L is more discriminative than the EQ-5D-3L in patients with diabetes in Singapore. Value Health Reg Issues. 2016;9:57–62.CrossRef Wang P, Luo N, Tai E, Thumboo J. The EQ-5D-5L is more discriminative than the EQ-5D-3L in patients with diabetes in Singapore. Value Health Reg Issues. 2016;9:57–62.CrossRef
8.
Zurück zum Zitat Conner-Spady BL, Marshall DA, Bohm E, Dunbar MJ, Loucks L, Al Khudairy A, et al. Reliability and validity of the EQ-5D-5L compared to the EQ-5D-3L in patients with osteoarthritis referred for hip and knee replacement. Qual Life Res. 2015;24(7):1775–84.CrossRef Conner-Spady BL, Marshall DA, Bohm E, Dunbar MJ, Loucks L, Al Khudairy A, et al. Reliability and validity of the EQ-5D-5L compared to the EQ-5D-3L in patients with osteoarthritis referred for hip and knee replacement. Qual Life Res. 2015;24(7):1775–84.CrossRef
9.
Zurück zum Zitat Golicki D, Niewada M, Buczek J, Karlińska A, Kobayashi A, Janssen M, et al. Validity of EQ-5D-5L in stroke. Qual Life Res. 2015;24(4):845–50.CrossRef Golicki D, Niewada M, Buczek J, Karlińska A, Kobayashi A, Janssen M, et al. Validity of EQ-5D-5L in stroke. Qual Life Res. 2015;24(4):845–50.CrossRef
10.
Zurück zum Zitat Janssen MF, Bonsel GJ, Luo N. Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. Pharmacoeconomics. 2018;36(6):675–97.CrossRef Janssen MF, Bonsel GJ, Luo N. Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. Pharmacoeconomics. 2018;36(6):675–97.CrossRef
11.
Zurück zum Zitat Van Hout B, Janssen M, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–15.CrossRef Van Hout B, Janssen M, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–15.CrossRef
12.
Zurück zum Zitat Buchholz I, Thielker K, Feng Y-S, Kupatz P, Kohlmann T. Measuring changes in health over time using the EQ-5D 3L and 5L: a head-to-head comparison of measurement properties and sensitivity to change in a German inpatient rehabilitation sample. Qual Life Res. 2015;24(4):829–35.CrossRef Buchholz I, Thielker K, Feng Y-S, Kupatz P, Kohlmann T. Measuring changes in health over time using the EQ-5D 3L and 5L: a head-to-head comparison of measurement properties and sensitivity to change in a German inpatient rehabilitation sample. Qual Life Res. 2015;24(4):829–35.CrossRef
13.
Zurück zum Zitat Jia Y, Cui F, Li L, Zhang D, Zhang G, Wang F, et al. Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Qual Life Res. 2014;23(8):2355–63.CrossRef Jia Y, Cui F, Li L, Zhang D, Zhang G, Wang F, et al. Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Qual Life Res. 2014;23(8):2355–63.CrossRef
14.
Zurück zum Zitat Golicki D, Niewada M, Karlińska A, Buczek J, Kobayashi A, Janssen M, et al. Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients. Qual Life Res. 2015;24(6):1555–63.CrossRef Golicki D, Niewada M, Karlińska A, Buczek J, Kobayashi A, Janssen M, et al. Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients. Qual Life Res. 2015;24(6):1555–63.CrossRef
15.
Zurück zum Zitat Hunger M, Sabariego C, Stollenwerk B, Cieza A, Leidl R. Validity, reliability and responsiveness of the EQ-5D in German stroke patients undergoing rehabilitation. Qual Life Res. 2012;21(7):1205–16.CrossRef Hunger M, Sabariego C, Stollenwerk B, Cieza A, Leidl R. Validity, reliability and responsiveness of the EQ-5D in German stroke patients undergoing rehabilitation. Qual Life Res. 2012;21(7):1205–16.CrossRef
16.
Zurück zum Zitat Krabbe PF, Peerenboom L, Langenhoff BS, Ruers TJ. Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual Life Res. 2004;13(7):1247–53.CrossRef Krabbe PF, Peerenboom L, Langenhoff BS, Ruers TJ. Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual Life Res. 2004;13(7):1247–53.CrossRef
17.
Zurück zum Zitat Hurst N, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol. 1997;36(5):551–9.CrossRef Hurst N, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol. 1997;36(5):551–9.CrossRef
18.
Zurück zum Zitat Luo N, Cheung YB, Ng R, Lee CF. Mapping and direct valuation: do they give equivalent EQ-5D-5L index scores? Health Quality Life Outcomes. 2015;13(1):166.CrossRef Luo N, Cheung YB, Ng R, Lee CF. Mapping and direct valuation: do they give equivalent EQ-5D-5L index scores? Health Quality Life Outcomes. 2015;13(1):166.CrossRef
19.
Zurück zum Zitat Fung SS, Luis J, Hussain B, Bunce C, Hingorani M, Hancox J. Patient-reported outcome measuring tools in cataract surgery: clinical comparison at a tertiary hospital. J Cataract Refract Surg. 2016;42(12):1759–67.CrossRef Fung SS, Luis J, Hussain B, Bunce C, Hingorani M, Hancox J. Patient-reported outcome measuring tools in cataract surgery: clinical comparison at a tertiary hospital. J Cataract Refract Surg. 2016;42(12):1759–67.CrossRef
20.
Zurück zum Zitat Ang M, Fenwick E, Wong TY, Lamoureux E, Luo N. Utility of EQ-5D to assess patients undergoing cataract surgery. Optom Vis Sci. 2013;90(8):861–6.CrossRef Ang M, Fenwick E, Wong TY, Lamoureux E, Luo N. Utility of EQ-5D to assess patients undergoing cataract surgery. Optom Vis Sci. 2013;90(8):861–6.CrossRef
21.
Zurück zum Zitat Feeny D, Spritzer K, Hays RD, Liu H, Ganiats TG, Kaplan RM, Palta M, Fryback DG. Agreement about identifying patients who change over time: cautionary results in cataract and heart failure patients. Med Decis Making. 2012;32(2):273–86.CrossRef Feeny D, Spritzer K, Hays RD, Liu H, Ganiats TG, Kaplan RM, Palta M, Fryback DG. Agreement about identifying patients who change over time: cautionary results in cataract and heart failure patients. Med Decis Making. 2012;32(2):273–86.CrossRef
22.
Zurück zum Zitat Groessl EJ, Liu L, Sklar M, Tally SR, Kaplan RM, Ganiats TG. Measuring the impact of cataract surgery on generic and vision-specific quality of life. Qual Life Res. 2013;22(6):1405–14.CrossRef Groessl EJ, Liu L, Sklar M, Tally SR, Kaplan RM, Ganiats TG. Measuring the impact of cataract surgery on generic and vision-specific quality of life. Qual Life Res. 2013;22(6):1405–14.CrossRef
23.
Zurück zum Zitat Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53–72.CrossRef Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53–72.CrossRef
24.
Zurück zum Zitat Luo N, Wang P, Thumboo J, Lim Y-W, Vrijhoef HJ. Valuation of EQ-5D-3L health states in Singapore: modeling of time trade-off values for 80 empirically observed health states. Pharm Econ. 2014;32(5):495–507.CrossRef Luo N, Wang P, Thumboo J, Lim Y-W, Vrijhoef HJ. Valuation of EQ-5D-3L health states in Singapore: modeling of time trade-off values for 80 empirically observed health states. Pharm Econ. 2014;32(5):495–507.CrossRef
25.
Zurück zum Zitat Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–108.CrossRef Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–108.CrossRef
26.
Zurück zum Zitat Oppe M, Rand-Hendriksen K, Shah K, Ramos-Goni JM, Luo N. EuroQol protocols for time trade-off valuation of health outcomes. Pharmacoeconomics. 2016;34(10):993–1004.CrossRef Oppe M, Rand-Hendriksen K, Shah K, Ramos-Goni JM, Luo N. EuroQol protocols for time trade-off valuation of health outcomes. Pharmacoeconomics. 2016;34(10):993–1004.CrossRef
28.
Zurück zum Zitat Devlin NJ, Shah KK, Feng Y, Mulhern B, Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27(1):7–22.CrossRef Devlin NJ, Shah KK, Feng Y, Mulhern B, Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27(1):7–22.CrossRef
29.
Zurück zum Zitat Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–92.CrossRef Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–92.CrossRef
30.
Zurück zum Zitat Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI®): concepts, measurement properties and applications. Health Quality Life Outcomes. 2003;1(1):54.CrossRef Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI®): concepts, measurement properties and applications. Health Quality Life Outcomes. 2003;1(1):54.CrossRef
31.
Zurück zum Zitat Furlong W, Feeny D, Torrance G, Goldsmith C, DePauw S, Zhu Z, et al. Multiplicative multi-attribute utility function for the Health Utilities Index Mark 3 (HUI3) system: a technical report. Hamilton: Centre for Health Economics and Policy Analysis (CHEPA), McMaster University; 1998. Furlong W, Feeny D, Torrance G, Goldsmith C, DePauw S, Zhu Z, et al. Multiplicative multi-attribute utility function for the Health Utilities Index Mark 3 (HUI3) system: a technical report. Hamilton: Centre for Health Economics and Policy Analysis (CHEPA), McMaster University; 1998.
32.
Zurück zum Zitat Steinberg EP, Tielsch JM, Schein OD, Javitt JC, Sharkey P, Cassard SD, et al. The VF-14: an index of functional impairment in patients with cataract. Arch Ophthalmol. 1994;112(5):630–8.CrossRef Steinberg EP, Tielsch JM, Schein OD, Javitt JC, Sharkey P, Cassard SD, et al. The VF-14: an index of functional impairment in patients with cataract. Arch Ophthalmol. 1994;112(5):630–8.CrossRef
33.
Zurück zum Zitat Lamoureux EL, Pesudovs K, Thumboo J, Saw S-M, Wong TY. An evaluation of the reliability and validity of the visual functioning questionnaire (VF-11) using Rasch analysis in an Asian population. Invest Ophthalmol Vis Sci. 2009;50(6):2607–13.CrossRef Lamoureux EL, Pesudovs K, Thumboo J, Saw S-M, Wong TY. An evaluation of the reliability and validity of the visual functioning questionnaire (VF-11) using Rasch analysis in an Asian population. Invest Ophthalmol Vis Sci. 2009;50(6):2607–13.CrossRef
34.
Zurück zum Zitat Bowker AH. A test for symmetry in contingency tables. J Am Stat Assoc. 1948;43(244):572–4.CrossRef Bowker AH. A test for symmetry in contingency tables. J Am Stat Assoc. 1948;43(244):572–4.CrossRef
35.
Zurück zum Zitat Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures statistics and strategies for evaluation. Control Clin Trials. 1991;12(4):S142–58.CrossRef Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures statistics and strategies for evaluation. Control Clin Trials. 1991;12(4):S142–58.CrossRef
36.
Zurück zum Zitat Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Erlbaum Associates; 1988. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Erlbaum Associates; 1988.
37.
Zurück zum Zitat Mooney CZ, Duval RD, Duvall R. Bootstrapping: a nonparametric approach to statistical inference: Sage; 1993. Mooney CZ, Duval RD, Duvall R. Bootstrapping: a nonparametric approach to statistical inference: Sage; 1993.
38.
Zurück zum Zitat McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain. 2004;111(1–2):77–83.CrossRef McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain. 2004;111(1–2):77–83.CrossRef
39.
Zurück zum Zitat Buchholz I, Janssen MF, Kohlmann T, Feng YS. A systematic review of studies comparing the measurement properties of the three-level and five-level versions of the EQ-5D. Pharmacoeconomics. 2018;36(6):645–61.CrossRef Buchholz I, Janssen MF, Kohlmann T, Feng YS. A systematic review of studies comparing the measurement properties of the three-level and five-level versions of the EQ-5D. Pharmacoeconomics. 2018;36(6):645–61.CrossRef
40.
Zurück zum Zitat Yang F, Devlin N, Luo N. Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments. Eur J Health Econ. 2018 (Epub). Yang F, Devlin N, Luo N. Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments. Eur J Health Econ. 2018 (Epub).
41.
Zurück zum Zitat Alava MH, Wailoo A, Grimm S, Pudney S, Gomes M, Sadique Z, et al. EQ-5D-5L versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom. Value Health. 2018;21(1):49–56.CrossRef Alava MH, Wailoo A, Grimm S, Pudney S, Gomes M, Sadique Z, et al. EQ-5D-5L versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom. Value Health. 2018;21(1):49–56.CrossRef
42.
Zurück zum Zitat Mulhern B, Feng Y, Shah K, Janssen MF, Herdman M, van Hout B, Devlin N. Comparing the UK EQ-5D-3L and English EQ-5D-5L value sets. Pharmacoeconomics. 2018;36(6):699–713.CrossRef Mulhern B, Feng Y, Shah K, Janssen MF, Herdman M, van Hout B, Devlin N. Comparing the UK EQ-5D-3L and English EQ-5D-5L value sets. Pharmacoeconomics. 2018;36(6):699–713.CrossRef
43.
Zurück zum Zitat Groessl EJ, Liu L, Sklar M, Tally SR, Kaplan RM, Ganiats TG. Measuring the impact of cataract surgery on generic and vision-specific quality of life. Qual Life Res. 2013;22(6):1405–14.CrossRef Groessl EJ, Liu L, Sklar M, Tally SR, Kaplan RM, Ganiats TG. Measuring the impact of cataract surgery on generic and vision-specific quality of life. Qual Life Res. 2013;22(6):1405–14.CrossRef
44.
Zurück zum Zitat Luo N, Wang X, Ang M, Finkelstein EA, Aung T, Wong T-Y, et al. A vision “bolt-on” item could increase the discriminatory power of the EQ-5D index score. Value Health. 2015;18(8):1037–42.CrossRef Luo N, Wang X, Ang M, Finkelstein EA, Aung T, Wong T-Y, et al. A vision “bolt-on” item could increase the discriminatory power of the EQ-5D index score. Value Health. 2015;18(8):1037–42.CrossRef
45.
Zurück zum Zitat Longworth L, Yang Y, Young T, Mulhern B, Hernandez Alava M, Mukuria C, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technology Assessment. 2014. Longworth L, Yang Y, Young T, Mulhern B, Hernandez Alava M, Mukuria C, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technology Assessment. 2014.
46.
Zurück zum Zitat Hays RD, Kim S, Spritzer KL, Kaplan RM, Tally S, Feeny D, et al. Effects of mode and order of administration on generic health-related quality of life scores. Value Health. 2009;12(6):1035–9.CrossRef Hays RD, Kim S, Spritzer KL, Kaplan RM, Tally S, Feeny D, et al. Effects of mode and order of administration on generic health-related quality of life scores. Value Health. 2009;12(6):1035–9.CrossRef
47.
Zurück zum Zitat Ferreira LN, Ferreira PL, Pereira LN, Rowen D, Brazier J. Exploring the consistency of the SF-6D. Value Health. 2013;16(6):1023–31.CrossRef Ferreira LN, Ferreira PL, Pereira LN, Rowen D, Brazier J. Exploring the consistency of the SF-6D. Value Health. 2013;16(6):1023–31.CrossRef
48.
Zurück zum Zitat Wong CK, Mulhern B, Wan Y-F, Lam CL. Responsiveness was similar between direct and mapped SF-6D in colorectal cancer patients who declined. J Clin Epidemiol. 2014;67(2):219–27.CrossRef Wong CK, Mulhern B, Wan Y-F, Lam CL. Responsiveness was similar between direct and mapped SF-6D in colorectal cancer patients who declined. J Clin Epidemiol. 2014;67(2):219–27.CrossRef
49.
Zurück zum Zitat Abdin E, Subramaniam M, Vaingankar JA, Luo N, Chong SA. Population norms for the EQ-5D index scores using Singapore preference weights. Qual Life Res. 2015;24(6):1545–53.CrossRef Abdin E, Subramaniam M, Vaingankar JA, Luo N, Chong SA. Population norms for the EQ-5D index scores using Singapore preference weights. Qual Life Res. 2015;24(6):1545–53.CrossRef
50.
Zurück zum Zitat Sun S, Chen J, Johannesson M, et al. Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008. Qual Life Res. 2010;20(3):309–20.CrossRef Sun S, Chen J, Johannesson M, et al. Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008. Qual Life Res. 2010;20(3):309–20.CrossRef
Metadaten
Titel
EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery
verfasst von
Mihir Gandhi
Marcus Ang
Kelvin Teo
Chee Wai Wong
Yvonne Chung-Hsi Wei
Rachel Lee-Yin Tan
Mathieu F. Janssen
Nan Luo
Publikationsdatum
01.08.2019
Verlag
Springer International Publishing
Erschienen in
The Patient - Patient-Centered Outcomes Research / Ausgabe 4/2019
Print ISSN: 1178-1653
Elektronische ISSN: 1178-1661
DOI
https://doi.org/10.1007/s40271-018-00354-7

Weitere Artikel der Ausgabe 4/2019

The Patient - Patient-Centered Outcomes Research 4/2019 Zur Ausgabe